Ceragenix Announces Results from Phase IV Study of EpiCeram Meet All Primary and Secondary Endpoints
DENVER--(BUSINESS WIRE)--Apr 24, 2007 - Ceragenix Pharmaceuticals Inc. (OTCBB:CGXP) today announced positive results from its post-clearance marketing study comparing EpiCeram's(TM) efficacy to that of Cutivate(R) cream, a mid-strength topical steroid in the treatment of moderate-to-severe atopic d...EpiCeram Skin Barrier Emulsion
EpiCeram, is a topical non-steroidal skin care cream based on the research of Dr. Peter Elias for the treatment of atopic dermatitis (eczema). Ceragenix obtained FDA marketing clearance in April 2006. This prescription drug works as a moisturizer and barrier cream and is now on the market.News: Ceragenix Receives 510k Clearance of EpiCeram(R) for the ...
Ceragenix Pharmaceuticals, Inc., a biopharmaceutical company focused on infectious disease and dermatology, today announced it has received 510K clearance from the ...PromiusPharmaIntroducesEpiCeram
the launch of its first product, EpiCeram® Skin Barrier Emulsion. EpiCeram Emulsion is a novel prescription therapy for the treatment of ...Ceragenix Announces Results from Phase IV Study of EpiCeram(TM) Meet ...
Multi-Center Study Shows EpiCeram has Comparable Efficacy to Mid-Strength ... Both EpiCeram(TM) and Cutivate(R) produced significant improvement in patients' ...Ceragenix Pharmaceuticals Provides Update on EpiCeram(R)
EpiCeram(R) is a prescription only product intended for use to treat dry skin ... Ceragenix believes that EpiCeram(R) has the potential to become the foundation ...